1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D476DDFE7E67597E652580C600208768
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-best-practices-scientific-publications-strategy-alignment-effectiveness?opendocument
18
19opendocument
2018.212.222.217
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Scientific Publications

Best Practices in Scientific Publications Strategy: Alignment and Effectiveness

ID: 5449


Features:

10 Info Graphics

18 Data Graphics

240 Metrics

6 Narratives


Pages/Slides: 39


Published: 2017


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from Best Practices in Scientific Publications Strategy: Alignment and Effectiveness”

STUDY OVERVIEW

Bio-pharmaceutical organizations rely on scientific publications to inform the medical community about critical clinical trial data. With growing calls for transparency and data disclosure, global publications leaders find themselves in a balancing act—ensuring both scientific credibility and commercial viability.
Best Practices, LLC undertook benchmarking research to investigate how top pharmaceutical and biotechnology companies shape their global scientific publication strategies and plans to maintain credibility in the scientific community and deliver publications that drive brand success. In particular, this study provides benchmarks around publication strategy creation and data delivery, publication channel utilization across product lifecycle; and measuring publication effectiveness.

KEY TOPICS

  • Transition of Global Publications from Commercial to Clinical
  • Publication Plan Strategy and Delivery
  • Publication Content and Channels
  • Measuring Publication Effectiveness

KEY METRICS

  • Tactics to Communicate and Implement Publications Strategy with Key Stakeholders across the Organization
  • Changes in Publication Activities in Specific Areas
  • Delivery of Publication Plan
  • Regional Affiliates’ Publication Plan
  • How to Ensure Alignment among the Regional and Global Plans
  • Most Effective Publication Vehicles and Content Types for Publications at Each Phase of the Product Lifecycle
  • Important Target Audience for Publications at Each Phase of the Product Lifecycle
  • Medical Publication Strategy Development Stage
  • Last Stage for Involvement of the Publication Function
  • First Stage of Publishing an Abstract and a Manuscript
  • Publishing Output 2016 - Total Number of Publications, Abstracts and Manuscripts Produced
  • Total Number of Publications (by Type) Required During the Phase 3 to Launch Period for Market Entry
  • Mix of Publication Papers Appearing in Each of Three-tiers of Publications During Phase 3 to Launch Period
  • Important Channels for Publishing Clinical Results
  • Effective Measures to Evaluate Publication Management Program

SAMPLE KEY FINDINGS

  • Outsourcing on the Rise for Publication Plan Delivery: Eighty percent of study participants outsource some portion of the delivery of their publication plan. Outsourcing has grown in the last five years as a core strategy of publication plan delivery. In our 2011 study, 47% of companies handled all delivery work in-house, whereas only 5% did so in 2016.

METHODOLOGY


Best Practices, LLC engaged 20 leaders from 19 leading bio-pharmaceutical companies with direct experience working in scientific publishing. Almost 75% of participants are from the U.S. region.


Industries Profiled:
Pharmaceutical; Manufacturing; Biotech; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Research; Distribution; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Alexion Pharmaceuticals; AstraZeneca; Bayer; Biotronik; Bioventus; Celgene; Genentech; Karyopharm Therapeutics; KimberlyClark; Lonza Inc.; McKessonHBOC; Nobel Biocare; Novartis; Portola Pharmaceuticals; Roche; Sanofi; Sirtex; Teva Pharmaceutical Industries Ltd; UCB Pharma


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.